Pharmaceutical products will face 100% tariffs in the US unless companies reach an agreement.
Published On 03 Apr, 2026
The United States has announced a 100% tariff on pharmaceutical imports, intensifying pressure on global drug manufacturers. However, companies that successfully negotiate trade agreements may be exempt from the tariff. The decision is expected to reshape international pharmaceutical trade, potentially affecting drug prices, supply chains, and access to medicines worldwide.
The policy is set to have major implications for global drug manufacturers and could disrupt international supply chains and pricing in the healthcare sector.
